Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
about
Platelets and their role in cancer evolution and immune systemTargeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasisPlatelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.Vascular tumours in infants. Part II: vascular tumours of intermediate malignancy [corrected] and malignant tumours.Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules.CLEC-2 expression is maintained on activated platelets and on platelet microparticles.Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis.Thrombocytes Correlate with Lymphangiogenesis in Human Esophageal Cancer and Mediate Growth of Lymphatic Endothelial Cells In VitroC-type lectin like receptor 2 (CLEC-2) signals independently of lipid raft microdomains in platelets.Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets.The new era of the lymphatic system: no longer secondary to the blood vascular systemFucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2)Syk negatively regulates TLR4-mediated IFNβ and IL-10 production and promotes inflammatory responses in dendritic cells.The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis.The snake venom rhodocytin from Calloselasma rhodostoma- a clinically important toxin and a useful experimental tool for studies of C-type lectin-like receptor 2 (CLEC-2)Hypercoagulation in colorectal cancer: what can platelet indices tell us?Antiplatelet agents for cancer treatment: a real perspective or just an echo from the past?Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.The Potential Role of Senescence As a Modulator of Platelets and Tumorigenesis.A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey ()
P2860
Q26769754-137BC4B9-77D2-4E1E-9EE4-25A56D939C18Q28600973-DBED06C2-8EC4-4A12-BA1C-9A838B62CF32Q31133789-7C69A624-4D6E-482C-8DA5-F0025BFC6628Q33416117-D6F024FF-2211-4BAD-9128-72BCBEA455A0Q33425053-ABBA5A5E-5B0B-45A4-BE9B-60FBFECEEC04Q34284335-717D8C56-3092-4689-A851-0563FD3CC385Q34522088-0C499972-0829-45E1-9F8C-8E70563ADA19Q34806144-CA41AC5E-064A-41F5-AA47-E76C99DFDA5FQ34902163-9769D16A-BA02-425D-B39E-20AD4B1DA380Q35561060-4A6DF230-B866-4B66-87C2-56DF6B5E28DEQ35852994-672FE11E-F3DF-40CA-BCD8-FDEEC7AB9C7FQ36685191-5454B4FB-00FE-4E3B-818E-BBB8F1A7B6F9Q37660568-94D7C042-6CE2-4697-A8EC-75C4D476D862Q38044830-DDDF3171-FE18-4F04-9B15-06F99A454FD3Q38099700-EFB25B7A-4655-4FAC-82A0-66CBC08F3131Q38246328-814F5751-5931-41A7-A32E-87B9365D3766Q41420993-E79C9B62-AC92-48E3-A364-2C262C5867DBQ47094540-80FDF51D-C13B-4098-9476-105AED89986EQ50143864-B8D10484-F21D-489C-87E0-DC20F98A2BBAQ57117084-BF9CD119-0C1C-4C9C-85CC-79BB68AB5F5C
P2860
Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Essential in vivo roles of the ...... enesis and thrombus formation.
@en
Essential in vivo roles of the ...... enesis and thrombus formation.
@nl
type
label
Essential in vivo roles of the ...... enesis and thrombus formation.
@en
Essential in vivo roles of the ...... enesis and thrombus formation.
@nl
prefLabel
Essential in vivo roles of the ...... enesis and thrombus formation.
@en
Essential in vivo roles of the ...... enesis and thrombus formation.
@nl
P2860
P356
P1476
Essential in vivo roles of the ...... enesis and thrombus formation.
@en
P2093
Katsue Suzuki-Inoue
P2860
P304
P356
10.1093/JB/MVR079
P577
2011-06-21T00:00:00Z